X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs NOVARTIS - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD NOVARTIS BIOCON LTD/
NOVARTIS
 
P/E (TTM) x 77.9 363.5 21.4% View Chart
P/BV x 7.3 17.9 41.0% View Chart
Dividend Yield % 0.2 1.6 10.5%  

Financials

 BIOCON LTD   NOVARTIS
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
NOVARTIS
Mar-16
BIOCON LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,162982 118.3%   
Low Rs483556 86.7%   
Sales per share (Unadj.) Rs194.6252.9 76.9%  
Earnings per share (Unadj.) Rs34.462.1 55.4%  
Cash flow per share (Unadj.) Rs48.363.3 76.3%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.11.3 9.4%  
Book value per share (Unadj.) Rs241.9363.6 66.5%  
Shares outstanding (eoy) m200.0031.96 625.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.23.0 139.0%   
Avg P/E ratio x23.912.4 193.1%  
P/CF ratio (eoy) x17.012.2 140.2%  
Price / Book Value ratio x3.42.1 160.7%  
Dividend payout %2.916.1 18.1%   
Avg Mkt Cap Rs m164,44024,580 669.0%   
No. of employees `0009.20.8 1,227.9%   
Total wages/salary Rs m7,4701,801 414.7%   
Avg. sales/employee Rs Th4,213.910,748.9 39.2%   
Avg. wages/employee Rs Th809.02,395.2 33.8%   
Avg. net profit/employee Rs Th745.22,641.1 28.2%   
INCOME DATA
Net Sales Rs m38,9118,083 481.4%  
Other income Rs m1,571829 189.4%   
Total revenues Rs m40,4828,913 454.2%   
Gross profit Rs m9,795234 4,182.3%  
Depreciation Rs m2,77237 7,553.1%   
Interest Rs m2602 14,444.4%   
Profit before tax Rs m8,3341,025 813.0%   
Minority Interest Rs m1630-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m1,616752 214.9%   
Profit after tax Rs m6,8811,986 346.5%  
Gross profit margin %25.22.9 868.8%  
Effective tax rate %19.473.4 26.4%   
Net profit margin %17.724.6 72.0%  
BALANCE SHEET DATA
Current assets Rs m40,47712,678 319.3%   
Current liabilities Rs m16,7832,433 689.8%   
Net working cap to sales %60.9126.7 48.0%  
Current ratio x2.45.2 46.3%  
Inventory Days Days6033 182.3%  
Debtors Days Days8322 368.4%  
Net fixed assets Rs m45,07369 65,134.4%   
Share capital Rs m1,000160 625.8%   
"Free" reserves Rs m47,37711,460 413.4%   
Net worth Rs m48,37711,621 416.3%   
Long term debt Rs m21,0820-   
Total assets Rs m93,94214,400 652.4%  
Interest coverage x33.1570.5 5.8%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.40.6 73.8%   
Return on assets %7.613.8 55.1%  
Return on equity %14.217.1 83.2%  
Return on capital %12.623.6 53.5%  
Exports to sales %00.7 0.0%   
Imports to sales %018.6 0.0%   
Exports (fob) Rs mNA60 0.0%   
Imports (cif) Rs mNA1,503 0.0%   
Fx inflow Rs m12,988186 6,971.6%   
Fx outflow Rs m7,8991,821 433.8%   
Net fx Rs m5,089-1,635 -311.3%   
CASH FLOW
From Operations Rs m6,4002,531 252.9%  
From Investments Rs m-4,985-8,270 60.3%  
From Financial Activity Rs m-1,775-386 460.2%  
Net Cashflow Rs m-473-6,125 7.7%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 2.0 420.0%  
FIIs % 10.7 1.6 668.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 21.5 92.6%  
Shareholders   109,995 41,647 264.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Down; Tata Steel Top Loser(09:30 am)

Asian stocks rose in morning trade on Monday, after the US's S&P 500 extended its winning streak on Friday to six days. Markets in the Greater China region remain closed for the Lunar New Year holiday.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 19, 2018 11:35 AM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS